Posts

The updated COVID-19 boosters from Pfizer Inc./BioNTech SE and Moderna helped prevent symptomatic infections against the new XBB-related subvariants, offering new evidence of how the vaccines perform against these fast-spreading strains, U.S. officials said today.

The drug was being tested in combination with androgen deprivation therapy and Xtandi, made by Pfizer Inc and Astellas Pharma Inc., in patients with hormone-sensitive prostate cancer that has spread to other parts of the body.

Last week the FDA and CDC flagged a potential link between the Pfizer/BioNTech coronavirus vaccine and stroke in older adults; today Israel’s coronavirus task force said it reviewed all its data and did not find an issue.

“EMA can confirm that to date no such signal has been identified in the EU. EMA will continue to evaluate all available data to determine whether emerging safety information could point to a similar signal in the EU,” the agency stated.

In an expansion of the company’s “An Accord for a Healthier World” program, which is aimed at increasing access to innovative treatments in some of the world’s poorest countries, Pfizer said it will now offer a total of 500 products.

Chinese authorities have acknowledged that supplies of Paxlovid are still insufficient to meet demand, even as Pfizer CEO Albert Bourla said last week that thousands of courses of the treatment were shipped to the country last year and in the past couple of weeks millions more were shipped.

Pfizer forecasted stable growth in the coming years, driven by a strong product push to cushion its non-COVID business and exclusivity losses, according to company chairman and Chief Executive Officer Albert Bourla, M.D., Monday.

Pfizer Inc. is not in talks with Chinese authorities to license a generic version of its COVID-19 treatment Paxlovid for use there, but is in discussions about a price for the branded product, Chief Executive Albert Bourla said on Monday.

The U.S. Supreme Court on Monday turned away Pfizer Inc.’s bid to revive its plan to cover out-of-pocket expenses of Medicare patients for drugs costing $225,000 a year to treat a rare heart condition after federal officials found that the drugmaker’s arrangement could amount to illegal kickbacks.

The Omicron-adapted COVID-19 vaccine booster developed by Pfizer Inc. and BioNTech SE sharply reduced hospitalizations among older patients, Israeli researchers said on Monday, in some of the first evidence of the jab’s real-world effectiveness.